Clinical Trial Search

Primary: Percentage of Participants Achieving American College of Rheumatology 20 Index (ACR20) — 19.5; 53.3; 48.0 Percentage of Participants — p=<0.001

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 18; 14; 1; 1 participants

Primary: Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 — 2.4; -52.0; -32.6 percent (%) change — p=<0.001

Primary: Number of Subjects With a Reduction in the Disease Activity Index of >3, or Clinical Remission. — 10; 0 Participants — p=0.03

Primary: Part A: Weighted Mean Change From Baseline in Pain Intensity Over the First 8 Hours Post-Dose Using VAS — -3.8; -47.4; -12.7 mm

Primary: Number of Participants With Potentially Clinically Important (PCI) Change From Baseline in Vital Signs — 0; 0; 0; 2 participants

Primary: Snoring Severity Scale — -4.1 units on a scale — p=< 0.0001

Primary: The Total Blood Loss — 376.73; 339.81 ml

Primary: Sitting Assessment Scale — 12.56; 15.06 units on a scale — p=0.001

Primary: Salmeterol Protected Methacholine Challenge PC20 — 1.8; 1.7 mg/ml on log base 2 scale

Primary: Percentage of Subjects With Human Serum Bactericidal Activity (hSBA)≥1:4 — 84; 84; 84; 7 Percentage of subjects

Primary: Percentage of Participants With JE Seroprotection Before and Following a Booster Dose of IMOJEV Given One Year After Primary Immunization — 93.5; 100.0 Percentage of…

Primary: Change From Baseline in Tinnitus Reaction on the Tinnitus Handicap Questionnaire Scores (0-100) at 4 Months — 22.03; 24.9; 23.7; 25.4 units on a scale — p=>0.05

Primary: Pancreatic Fat Content — 9.6; 13.0 Percentage of fat

Primary: Percentage of Participants Who Achieve Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 97.6 percentage of participants